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MethoctramineThe GluN3 subunits of the N-methyl-D-aspartate (NMDA) receptor are known to reduce its Ca2+ permeability and
Mg2+ sensitivity, however, little is known about their effects on other channel blockers. cRNAs for rat NMDA recep-
tor subunits were injected into Xenopus oocytes and responses to NMDA and glycinewere recorded using two elec-
trode voltage clamp. Channel block of receptors containing GluN1-1a/2A, GluN1-1a/2A/3A or GluN1-1a/2A/3B
subunits was characterised using Mg2+, memantine, MK-801, philanthotoxin-343 and methoctramine. IC50 values
for Mg2+ and memantine increased when receptors contained GluN3A subunits and were further increased when
they containedGluN3B, e.g. IC50s at−75mV for blockofGluN1-1a/2A, GluN1-1a/2A/3AandGluN1-1a/2A/3B recep-
tors respectivelywere 4.2, 22.4 and 40.1 μMforMg2+, and2.5, 7.5 and 17.5 μMformemantine. Blocking activitywas
found to be fully or partially restored when G or R (at the N and N+1 sites respectively) were mutated to N in
GluN3A. Thus, the changes cannot be attributed to the loss of the N or N+1 sites alone, but rather involve both
sites or residues elsewhere. Block by MK-801 and philanthotoxin-343 was also reduced by GluN3A, most strongly
at−100mV but not at−50mV, and by GluN3B at all Vh. Methoctramine was the least sensitive to introduction
of GluN3 subunits suggesting a minimal interaction with the N and N+1 sites. We conclude that GluN3B-
containing receptors provide increased resistance to channel block compared to GluN3A-containing receptors and
this must be due to differences outside the deep pore region (N site and deeper).
© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
N-methyl-D-aspartate (NMDA) receptors are a subgroup of the
ionotropic glutamate receptor family (Traynelis et al., 2010) that are
the products of seven genes giving rise to GluN1, GluN2A-D and
GluN3A-B subunits. GluN1 undergoes variable splicing producing eight
variants (GluN1-1a to GluN1-4a and GluN1-1b to 1-4b) (Dingledine
et al., 1999). Most NMDA receptors are formed by the assembly of two
GluN1 subunits and twoGluN2 subunits in a 1/2/1/2 orientation forming
a pore (Sobolevsky et al., 2009). GluN2 is activated by glutamate while
GluN1 is activated by glycine. GluN3 may combine with GluN1 and
GluN2 to form a functional receptor where, like GluN1, it contributes a
glycine binding site.
The GluN3 subunits are thought to act in a dominant negative
manner reducing block by Mg2+ and Ca2+ permeability (Sasaki et al.,
2002). Differences may be due to amino acid changes at the so called
‘N site’ selectivity ﬁlter, known to be a binding site for Mg2+ (Wollmuth
et al., 1998); this is N in both GluN1 and GluN2 subunits but G in GluN3sity of Nottingham, University
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ellor).
Road, Pampisford, Cambridge,
 license.subunits (● in Fig. 1A). Additionally, the N+1 site, also thought to play
a role in Mg2+ block, becomes a positively charged R in GluN3 subunits
rather than S or N in GluN1 and GluN2 respectively (○ in Fig. 1A).
There have also been reports of glycine gated receptors that are
formed fromGluN1 andGluN3 subunits following expression in Xenopus
oocytes (Chatterton et al., 2002); these receptors have been found on
white matter of the optic nerve (Pina-Crespo et al., 2010), but it is not
yet clear if they exist in neurones.
The activity of open-channel blockers on GluN3 containing receptors
has yet to be fully explored. The IC50 for Mg2+ has been shown to in-
crease 14-fold in transgenic mice over-expressing GluN3A compared
with controls (Tong et al., 2008). Other studies investigating Mg2+
block have only used a small range of concentrations with variable out-
comes, possibly because they have employed different subunit combi-
nations and expression systems (Cavara et al., 2010; Sasaki et al.,
2002; Yamakura et al., 2005). Further investigation of the endogenous
blocker is necessary to generate a more complete picture of Mg2+
block of different GluN3-containing receptors which is important for
interpreting function in vivo. It is also currently unknown if the well-
known NMDA receptor channel blockers memantine and MK-801 are
inﬂuenced by GluN3 subunits or whether block by the polyamine-
containing philanthotoxins (PhTXs) is reduced in a similar manner as
with AMPA receptors, where an R in the pore prevents block (Brackley
et al., 1993).
BA
Fig. 1. Comparison of ionotropic glutamate receptor sequences and NMDA receptor antagonists used in this study. A, Sequence alignment of the M2-M3 regions of GluA1, GluA2,
GluN1-1a, GluN2A, GluN3A and GluN3B subunits. Highlighted with ● is the Q/R/N site and ○ is the N+1 site. Other amino acids of interest are indicated by ▲ and numbered by
their relationship to the N site. Highlighted in black are conserved amino acids. B, 2-D structures of memantine, (+)-MK-801, PhTX-343 and methoctramine.
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block of NMDA receptors by Mg2+, memantine, (+)-MK-801 and
PhTX-343 (Fig. 1B), while doing a direct comparison between GluN3A
andGluN3Bmayhelp elucidate their role in vivo.We also include another
polyamine-containing compound, methoctramine (Fig. 1B), a weakly
voltage-dependent inhibitor of NMDA receptors in rat cortical neurones
(that also blocks muscarinic and nicotinic acetylcholine receptors, and
TRPV1 channels), that has not been tested at recombinant NMDA recep-
tors (Melchiorre et al., 2003; Mellor et al., 2004).
2. Materials and methods
2.1. Materials
PhTX-343 was a gift from Professors Jerzy Jaroszewski and
Kristian Strømgaard, Department of Medicinal Chemistry, University
of Copenhagen, Denmark. Methoctramine was a gift from Professors
Carlo Melchiorre and Anna Minarini, Department of Pharmaceutical
Sciences, University of Bologna, Italy. All other antagonists (memantine,
(+)-MK-801) and reagents were from Sigma-Aldrich-RBI (Poole, UK).
NMDA was from Ascent Scientiﬁc (Bristol, UK).
2.2. Molecular biology
NMDA receptor clones used were GluN1-1a and GluN2A in pRK7,
and GluN3A and GluN3B in pcDNA3.1 (gift from Dr. Dongxian Zhang,
Burnham Institute, La Jolla, CA), which were conﬁrmed by sequencing.
Mutations were introduced using the QuikChange site-directed muta-
genesis kit (Stratagene Cloning Systems, UK). Wild-type and mutant
plasmids were linearised using the appropriate restriction enzyme and
cRNA transcripts were synthesised using the mMESSAGE mMACHINE
kit (Ambion). Transcripts were dissolved in H2O to a ﬁnal concentration
of 1 μg/μl and stored at−80 °C until required.
2.3. Oocyte preparation
Oocytes were obtained by ovariectomy of female Xenopus laevis
(European Xenopus Resource Centre, University of Portsmouth, UK)anesthetized with 2 g/L ethyl 3-aminobenzoate methanesulfonic
acid (MS-222). The animals were humanely killed before oocyte
collection in order to obtain schedule 1 status for the study. This
protocol was approved by the Committee on Animal Resources,
University of Nottingham. Oocytes were prepared for injection by
treating fragments of ovary with 0.2 mg/ml collagenase (type 1A,
Sigma) in Ca2+-free GTP solution (96 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 2.5 mM Na-pyruvate, 0.5 mM theophylline, 50 mgml−1 genta-
micin sulfate and 5 mM HEPES, pH 7.5 with NaOH) for 1–2 h followed
by thorough rinsing. cRNA transcripts of either WT or mutant subunits
were mixed in a 1:1 ratio by weight for GluN1-1a/GluN2A or 1:1:3
ratio for GluN1-1a/GluN2A/GluN3(A or B) to give a minimum concen-
tration of 50 ng/μL. Oocytes were injected with 50 nl of the mixture,
and then incubated at 19 °C for 48 h in GTP solution (96 mM NaCl,
2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 2.5 mM Na-pyruvate, 0.5 mM
theophylline, 50 mgml−1 gentamicin sulfate and 5 mM HEPES, pH 7.5
with NaOH) prior to experimentation.2.4. Electrophysiology
Single oocyteswere transferred to a perfusion bath and continuously
washed with saline containing 95 mM NaCl, 2 mM KCl, 2 mM CaCl2,
5 mM HEPES, pH 7.5 with NaOH. Microelectrodes were pulled from
borosilicate glass capillaries (TW150F-4, World Precision Instruments)
using a Sutter P-97 programmable puller and had resistances of
~0.5 MΩwhen ﬁlled with 3.0 M KCl. The oocytes were voltage clamped
at holding potentials (Vh) in the range of 0 to -100 mV using an
Axoclamp 2A (Axon Instruments), and output currentswere transferred
to a PC using a CED 1401 plus interface (Cambridge Electronic Design)
and WinEDR software (Dr. John Dempster, Institute of Pharmacy
and Biomedical Sciences, University of Strathclyde, UK). To assess
antagonist potencies, responses of NMDA receptors were elicited
by perfusion of saturating concentrations of NMDA and glycine in the
absence and presence of test compounds in the range of 0.01 to
100 μM. Once the response to NMDA/glycine had stabilized, antagonist
concentrations were applied sequentially (lowest to highest) until a
new stable current was obtained (in the absence of active NMDA recep-
tor antagonists, the current remains unaffected during this application
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were normalized to the control current in the absence of antagonist
(=100%). IC50 values were obtained by ﬁtting antagonist concentra-
tion–inhibition curves by the equation:
% control response ¼ 100= 1þ IC50= B½ ð ÞS
 
where [B] is the antagonist concentration and S is the Hill slope.
Curves were ﬁt using Graphpad Prism 5 and IC50 values were com-
pared by an extra sum-of-squares F‐testwith differences considered sig-
niﬁcant for Pb0.05. The inﬂuence of GluN3 on the current in response to
NMDA/glycine was compared using one-way ANOVA followed by
Bonferroni post-hoc comparisons, with differences considered signiﬁ-
cant for Pb0.05. I–V relationships were constructed by determining cur-
rent in response to NMDA/glycine at a range of holding potentials
between −100 and 0 mV in increments of 25 mV. Current was
normalised to that at −75 mV. Linear regression was carried out in
GraphPad Prism 5 between −50 and 0 mV and the X-intercept (ex-
trapolated for GluN1-1A/2A) was considered the reversal potential.
3. Results
3.1. GluN3 altered NMDA receptor properties
The mean steady‐state current in response to 100 μM NMDA plus
10 μM glycine showed a signiﬁcant reduction when GluN3A or
GluN3Bwere co-injected with GluN1-1a and GluN2A (Fig. 2A). Oocytes
injected with GluN1-1a, GluN2A and GluN3 subunits were tested with
1 mM glycine alone or with 1 mM Zn2+ but no signiﬁcant current was
recorded in three different batches of oocytes; both NMDA and glycine
were required to elicit a response (Fig. 2B). When I/V relationships
were produced the reversal potential for GluN1-1a/2A was 12.15 mV
and this was reduced for GluN1-1a/2A/3A containing receptors to
−2.65 mV (Fig. 2C, D). Concentration–response relationships forFig. 2. GluN3 subunits are incorporated into the NMDA receptors. A, Effect of subunit com
n=40–85). Signiﬁcant differences compared to GluN1-1a/2A within a voltage group are ind
a current in oocytes injected with GluN1-1a, GluN2A and GluN3A. Currents from the same
were obtained from six oocytes from three different batches (Vh=−50 mV). C,D, I/V relatio
evoked by application of 100 μM NMDA plus 10 μM glycine, normalised to that at −75 m
regression.NMDA (in the presence of 10 μM glycine) from oocytes injected with
GluN1-1a/2A, GluN1-1a/2A/3A or GluN1-1a/2A/3B were virtually sup-
erimposed, however, equivalent plots for glycine (in the presence of
100 μMNMDA) show curves shifted to the left for NMDA receptors con-
taining GluN3A or GluN3B (Supplementary Fig. 2).
3.2. The presence of GluN3A or GluN3B increased the IC50 for Mg
2+
The IC50 values for Mg2+ inhibition of all subunit combinations test-
ed are given in Fig. 3. Sample current traces at−75 mV and concentra-
tion–inhibition curves are shown in Fig. 4. The presence of GluN3
subunits caused a signiﬁcant increase in the IC50 for Mg2+ compared
withGluN1-1a/2A alone, and for GluN1-1a/2A/3B itwas found to be sig-
niﬁcantly higher than for GluN1-1a/2A/3A at all the voltages tested.
In order to explore the reasons why GluN3 subunits generally are
capable of reducing the effectiveness of open‐channel block we pre-
pared mutations at the N and N+1 sites of GluN3A, sites known to
be important for channel block, producing GluN3A(G729N) and
GluN3A(R730N). At -100 mV both GluN3A mutations signiﬁcantly re-
duced the IC50 compared with GluN3A wild-type (Pb0.0001 and
Pb0.01 respectively), but it remained signiﬁcantly higher than that
for GluN1-1a/2A for both GluN1-1a/2A/3A(G729N) (Pb0.0001) and
GluN1-1a/2A/3A(R730N) (Pb0.05). At −75 mV and −50 mV the
GluN3A mutations resulted in an IC50 for Mg2+ where GluN1-1a/2A/
3A(G729N) was again intermediate, being signiﬁcantly lower than
that for GluN1-1a/2A/3A (Pb0.0001) and signiﬁcantly higher than
that for GluN1-1a/2A (Pb0.01); while GluN1-1a/2A/3A(R730N) re-
stored the IC50 to levels that were not signiﬁcantly different to that
for GluN1-1a/2A.
3.3. Memantine had a similar pattern of block to Mg2+
The IC50 values for memantine inhibition of all subunit combina-
tions tested are given in Fig. 3. Sample current traces at −75 mV
and concentration–inhibition curves are shown in Fig. 5. The IC50 forposition on steady-state current. Bars represent mean current (error bars are 95% CI,
icated above the bars (*Pb0.05 or ***Pb0.001, Bonferroni). B, Glycine does not activate
oocyte exposed to glycine alone (1 mM) or NMDA/glycine (100/10 μM). Similar results
nships for oocytes injected with GluN1-1a/2A (C) or GluN1-1a/2A/3A (D). Current was
V and plotted as mean±S.E.M. Points between −50 mV and 0 mV are ﬁt by linear
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Fig. 3. Summary of the IC50 values for Mg2+, memantine, MK-801, PhTX-343 andmethoctramine block of the NMDA receptor subunit combinations tested. IC50s were obtained from
the concentration–inhibition curves given in Figs. 4–8 for GluN1-1a/2A, GluN1-1a/2A/3A and GluN1-1a/2A/3B, and in Supplementary Fig. 3 for GluN1-1a/2A/3A(G729N) and
GluN1-1a/2A/3A(R730N). Bars show IC50 (μM)±95% CI. Numbers in parentheses are the number of oocytes. Statistical comparisons were made with GluN1-1a/2A (*) or with
GluN1-1a/2A/3A (†) with signiﬁcance of difference accepted for *,†Pb0.05, **,††Pb0.01, ***,†††Pb0.001.
25D.W. McClymont et al. / European Journal of Pharmacology 686 (2012) 22–31memantine at −100 and −75 mV was signiﬁcantly increased for
GluN3-containing NMDA receptors compared with GluN1-1a/2A,
with that for GluN1-1a/2A/3B again being signiﬁcantly higher than
that for GluN1-1a/2A/3A (Pb0.0001). A similar increase was foundat −50 mV, but at this voltage the IC50s for GluN1-1a/2A/3A and
GluN1-1a/2A/3B were not signiﬁcantly different to each other.
At−100 and−75 mV GluN1-1a/2A/3A(G729N) led to a reduction
in IC50 which became signiﬁcantly lower than that for GluN1-1a/2A/
Fig. 4. Characterising the block of GluN3-lacking and GluN3-containing NMDA receptors by Mg2+. A–C, sample traces of currents from Xenopus oocytes injected with GluN1-1A/2A
(A), GluN1-1a/2A/3A (B) or GluN1-1a/2A/3B (C) and exposed to 100 μM NMDA plus 10 μM Gly with the addition of increasing concentrations of Mg2+ (10−8 to 10−4 M in 10-fold
increments) indicated by the arrows, with the last arrow indicating wash. Traces begin 3 s before the lowest Mg2+ concentration was applied by which point a stable current was
established; as this was after a variable period the ﬁrst part of the trace is not shown. All traces were recorded at a Vh of −75 mV. D–F, concentration–inhibition curves for Mg2+
block of 100 μM NMDA plus 10 μM Gly currents from Xenopus oocytes injected with GluN1-1A/2A (●, solid line), GluN1-1a/2A/3A (■, broken line) or GluN1-1a/2A/3B (♦, dotted
line). Points are means±S.E.M. for 6–7 oocytes. Curves are ﬁts to the equation given in the Materials and methods section and IC50s derived from these are given in Fig. 3.
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1a/2A (Pb0.05 at −100 mV; Pb0.0001 at −75 mV); GluN3A(R730N)
completely restored block so that the IC50 for memantine was not sig-
niﬁcantly different to that for GluN1-1a/2A. At−50 mV bothmutations
led to an intermediate IC50 that was both signiﬁcantly lower than that
for GluN1-1a/2A/3A (Pb0.0001) and signiﬁcantly higher than that for
GluN1-1a/2A (Pb0.01).3.4. MK-801 IC50 was mostly inﬂuenced by GluN3B
IC50 values for MK-801 inhibition of all subunit combinations tested
are given in Fig. 3. Sample current traces at−75 mVand concentration–
inhibition curves are shown in Fig. 6. At−100 mVMK-801 had an IC50
at GluN1-1a/2A which was signiﬁcantly lower than that for GluN1-1a/
2A/3A (Pb0.01) and GluN1-1a/2A/3B (Pb0.01), but the IC50s for the
latter two combinations were not signiﬁcantly different to each other.
At−75 and−50 mV the IC50 for MK-801 at GluN1-1a/2A/3B was sig-
niﬁcantly higher than GluN1-1a/2A and GluN1-1a/2A/3A (Pb0.0001)but there was no signiﬁcant difference between the IC50s of the latter
two combinations.
At −100 mV both the GluN3A mutations completely restored
block by MK-801 as the IC50 values were not signiﬁcantly different
to GluN1-1a/2A. Since GluN1-1a/2A/3A did not increase the IC50 at
−75 mV and−50 mV the mutations led to no change in potency ex-
cept for GluN3A(R730N) at−50 mV, where it actually increased the
potency and led to an IC50 that was signiﬁcantly lower than that for
GluN1-1a/2A (Pb0.01).
3.5. PhTX-343 block was only sensitive to GluN3 subunits at more
negative Vh
IC50 values for PhTX-343 inhibition of all subunit combinations
tested are given in Fig. 3. Sample current traces at −75 mV and con-
centration–inhibition curves are shown in Fig. 7. At -100 mV the IC50
for PhTX-343 was signiﬁcantly increased for GluN1-1a/2A/3A and
GluN1-1a/2A/3B compared with GluN1-1a/2A (Pb0.0001), while the
IC50s for the GluN3A- or GluN3B-containing receptors were not
Fig. 5. Characterising the block of GluN3-lacking and GluN3-containing NMDA receptors by memantine. A–C, sample traces of currents from Xenopus oocytes injected with GluN1-
1A/2A (A), GluN1-1a/2A/3A (B) or GluN1-1a/2A/3B (C) and exposed to 100 μM NMDA plus 10 μM Gly with the addition of increasing concentrations of memantine (10−8 to
10−4 M in 10-fold increments) indicated by the arrows, with the last arrow indicating wash. Traces begin 3 s before the lowest memantine concentration was applied by which
point a stable current was established; as thiswas after a variable period the ﬁrst part of the trace is not shown. All traceswere recorded at a Vh of−75 mV. D–F, concentration–inhibition
curves for memantine block of 100 μM NMDA plus 10 μM Gly currents from Xenopus oocytes injected with GluN1-1A/2A (●, solid line), GluN1-1a/2A/3A (■, broken line) or
GluN1-1a/2A/3B (♦, dotted line). Points are means±S.E.M. for 6–9 oocytes. Curves are ﬁts to the equation given in the Materials and methods section and IC50s derived
from these are given in Fig. 3.
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no signiﬁcant differences found in the IC50 for PhTX-343 for all the
subunits tested, except for that of GluN1-1a/2A/3B which was signiﬁ-
cantly higher than that of GluN1-1a/2A and GluN1-1a/2A/3A at
−50 mV (Pb0.01).
At −100 mV the GluN3A mutations partially restored the IC50 for
PhTX-343 which was signiﬁcantly reduced compared with GluN1-1a/
2A/3A (Pb0.01) but remained signiﬁcantly higher than GluN1-1a/2A
(Pb0.05).
3.6. Methoctramine inhibition was minimally affected by GluN3 subunits
IC50 values for methoctramine inhibition of all subunit com-
binations tested are given in Fig. 3. Sample current traces at
−75 mV and all concentration–inhibition curves are shown in
Fig. 8. At −100 mV there was a small but signiﬁcant increase in the
methoctramine IC50 for GluN1-1a/2A/3A (Pb0.01) and GluN1-1a/
2A/3B (Pb0.01) when compared with GluN1-1a/2A but it was not
different when compared to each other. At −75 mV the IC50 forGluN1-1a/2A/3B remained signiﬁcantly higher than that for both
GluN1-1a/2A and GluN1-1a/2A/3A (Pb0.01). At −50 mV there
were no signiﬁcant differences in the IC50s for methoctramine be-
tween GluN1-1a/2A, GluN1-1a/2A/3A and GluN1-1a/2A/3B.
At −100 mV the mutations led to the IC50 for methoctramine
being completely restored so that they were now not signiﬁcantly dif-
ferent to that for GluN1-1a/2A. At −75 mV, since the IC50 for
methoctramine at GluN1-1a/2A/3A was now not signiﬁcantly differ-
ent to that for GluN1-1a/2A the GluN3A mutations had no effect. At
−50 mV, the GluN3A(G729N) mutation led to an IC50 value that
was signiﬁcantly lower than that for GluN1-1a/2A (Pb0.01).
4. Discussion
GluN3 subunits have been frequently reported to have a negative
impact on NMDA mediated current and serves as an indicator of their
expression and incorporation into a functional NMDA receptor. In this
study, both GluN3A and GluN3B subunits reduced the mean ampli-
tude of NMDA/glycine evoked currents, presumably because of the
Fig. 6. Characterising the block of GluN3-lacking and GluN3-containing NMDA receptors by MK-801. A–C, sample traces of currents from Xenopus oocytes injected with GluN1-1A/2A
(A), GluN1-1a/2A/3A (B) or GluN1-1a/2A/3B (C) and exposed to 100 μM NMDA plus 10 μM Gly with the addition of increasing concentrations of MK-801 (10−8 to 10−4 M in 10-fold
increments) indicated by the arrows, with the last arrow indicating wash. Traces begin 3 s before the lowest MK-801 concentration was applied by which point a stable current was
established; as this was after a variable period the ﬁrst part of the trace is not shown. All traces were recorded at a Vh of −75 mV. D–F, concentration–inhibition curves for MK-801
block of 100 μM NMDA plus 10 μM Gly currents from Xenopus oocytes injected with GluN1-1A/2A (●, solid line), GluN1-1a/2A/3A (■, broken line) or GluN1-1a/2A/3B (♦, dotted
line). Points are means±S.E.M. for 5–7 oocytes. Curves are ﬁts to the equation given in the Materials and methods section and IC50s derived from these are given in Fig. 3.
28 D.W. McClymont et al. / European Journal of Pharmacology 686 (2012) 22–31previously reported reduced single channel current that may be due
to the charged R residue altering Ca2+ permeability, which is further
supported by the reduction in the reversal potential (Cavara et al.,
2010; Sasaki et al., 2002). Additionally, the sensitivity to glycine was
increased when the GluN3A or GluN3B subunits were co-expressed
with GluN1-1a and GluN2A. This change is consistent with previous
reports of the higher afﬁnity of the GluN3A ligand binding domain to
glycine and again conﬁrmed their presence in the expressed NMDA re-
ceptor (Yao andMayer, 2006). There have been reports of a GluN1/3 re-
ceptor population when GluN1, 2 and 3 were injected into Xenopus
oocytes, however such studies are limited by the fact that oocytes
express endogenous XenGluN2B (Ulbrich and Isacoff, 2008). In our
study glycine alone or together with Zn2+ failed to elicit a signiﬁcant
response. Glycine activated currents are thought to be rapidly desen-
sitising, although responses have been shown to be visible over a period
of 10 s meaning our experimental set-up would have detected them
(Madry et al., 2008). The lack of response may be because we were
using GluN1-1a which is a poor former of functional GluN1/3 receptors
(Smothers and Woodward, 2009). The fact that our concentration–
inhibition curves for the open-channel blockers were not obviouslybiphasic, while showing reproducible changes in IC50, led us to conclude
that the co-expression of GluN1, 2 and 3 led to a major population of
triheteromeric GluN1-1a/2A/3 receptors. However, we cannot rule out
the presence of a population of diheteromeric GluN1-1a/2A receptors,
in which case the effects of GluN3 subunits on receptor properties
reported here would be underestimated.
Mg2+, memantine and MK-801 are well established open-channel
blockers of NMDA receptors and studies of their binding sites show an
overlap at the N and N+1 sites, but also at some other residues in the
channel pore and vestibule (Kashiwagi et al., 2002). Our experiments
showing that GluN3A and GluN3B generally reduced block by Mg2+,
memantine and MK-801 led us to the hypothesis that the differences
in GluN3 subunits at the N site and N+1 site may be responsible for
this. However, the mutations GluN3A(G729N) and GluN3A(R730N)
did not always completely restore the blocking potency, therefore,
residues other than those at the N and N+1 sites may play a part.
In support of our ﬁndings it has been shown that in glycine-gated
GluN1-3a/3B receptors, mutation of the GluN3B N site or N+1 site
to N only partially restored block by 0.5 mMMg2+ (Cavara et al.,
2010). However, we cannot completely rule out the possibility that
Fig. 7. Characterising the block of GluN3-lacking and GluN3-containing NMDA receptors by PhTX-343. A–C, sample traces of currents from Xenopus oocytes injected with GluN1-1A/
2A (A), GluN1-1a/2A/3A (B) or GluN1-1a/2A/3B (C) and exposed to 100 μM NMDA plus 10 μM Gly with the addition of increasing concentrations of PhTX-343 (10−8 to 10−4 M in
10-fold increments) indicated by the arrows, with the last arrow indicating wash. Traces begin 3 s before the lowest PhTX-343 concentration was applied by which point a stable
current was established; as this was after a variable period the ﬁrst part of the trace is not shown. All traces were recorded at a Vh of−75 mV. D–F, concentration–inhibition curves
for PhTX-343 block of 100 μMNMDA plus 10 μMGly currents from Xenopus oocytes injected with GluN1-1A/2A (●, solid line), GluN1-1a/2A/3A (■, broken line) or GluN1-1a/2A/3B
(♦, dotted line). Points are means±S.E.M. for 6–11 oocytes. Curves are ﬁts to the equation given in the Materials and methods section and IC50s derived from these are given in
Fig. 3.
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into a channel complex, although in this situation we would expect a
consistent impact across all of the tested compounds.
Further residues have been identiﬁed on GluN1 and GluN2 subunits
that play a role in open-channel block. The W residue at position −8
(Fig. 1A) in GluN1 and GluN2 inﬂuences Mg2+ block, but mutations
here only resulted in a loss of activity if there was a loss of the aromatic
ring; this would be lost with GluN3A and GluN3B as they have N at this
position (Williams et al., 1998). Also, W-8 of GluN2B, when mutated to
N, which is found at that position in GluN3A and GluN3B, caused a large
drop in potency for several channel blockers including memantine and
MK-801 (Kashiwagi et al., 2002) and is therefore another likely candi-
date for reduced block of GluN3-containing channels.
The binding sites for PhTX-343 and methoctramine on NMDA
receptors have not yet been explored in detail. The strong voltage-
dependence of PhTX-343 inhibition shown here and in previous studies
(Mellor et al., 2003) implies that it has a binding site deep in the pore
while theweaker voltage-dependence ofmethoctramine inhibition im-
plies a shallower site in the pore. Studies of PhTX-343 with nicotinicacetylcholine receptors andAMPA receptors suggest that the polyamine
chain interacts with deep pore residues such as the hydrophilic and in-
termediate negatively charged rings of nicotinic acetylcholine receptors
or residues beyond the Q/R site of AMPA receptors (Andersen et al.,
2006; Brier et al., 2003; Tikhonov et al., 2002, 2004). The more hydro-
phobic headgroup of PhTX-343 is then thought to interact with residues
in thewider outer parts of the pore, i.e. outerM2andM1 residues in nic-
otinic acetylcholine receptors and M3 residues in AMPA receptors. It is
likely that PhTX-343 inhibits NMDA receptors with a similar binding
mode. In AMPA receptors, the Q/R site has been shown to be important
for the activity of polyamine toxins such as PhTX-343 and for block by
internal spermine that causes inward rectiﬁcation, as an R at the Q/R
site on the GluA2 subunit (Fig. 1A) of the AMPA receptor results in re-
ceptors that are not blocked by polyamines (Brackley et al., 1993;
Mellor, 2010; Strømgaard and Mellor, 2004). However, we found that
this was not entirely the case with the R at the N+1 site of GluN3 as
the loss of activity by PhTX-343 was only 4.67-fold at most. It may be
that the R+1 side-chain is less exposed to the pore and therefore has
less impact; it is known that in pore-loop channels the lining may be
Fig. 8. Characterising the block of GluN3-lacking and GluN3-containing NMDA receptors by methoctramine. A–C, sample traces of currents from Xenopus oocytes injected with
GluN1-1A/2A (A), GluN1-1a/2A/3A (B) or GluN1-1a/2A/3B (C) and exposed to 100 μM NMDA plus 10 μM Gly with the addition of increasing concentrations of methoctramine
(10−8 to 10−4 M in 10-fold increments) indicated by the arrows, with the last arrow indicating wash. Traces begin 3 s before the lowest methoctramine concentration was applied
by which point a stable current was established; as this was after a variable period the ﬁrst part of the trace is not shown. All traces were recorded at a Vh of −75 mV. D-F,
concentration–inhibition curves for methoctramine block of 100 μM NMDA plus 10 μM Gly currents from Xenopus oocytes injected with GluN1-1A/2A (●, solid line), GluN1-1a/
2A/3A (■, broken line) or GluN1-1a/2A/3B (♦, dotted line). Points are means±S.E.M. for 5–8 oocytes. Curves are ﬁts to the equation given in the Materials and methods section
and IC50s derived from these are given in Fig. 3.
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side-chains (Tikhonov et al., 2002). At NMDA receptors the polyamine
tail of anthraquinone and anthracene polyamines has been shown to in-
teract with the negatively charged E at position +5 of GluN1 (Fig. 1A),
located beyond the N site (Jin et al., 2007). The GluN3A and GluN3B
subunits have I or S in this position which could be interfering with
this binding. This difference may only manifest itself at highly negative
potential due to its deep position within the pore; as we demonstrated
here the distinction was lost as the Vh became less negative. Block
by anthraquinone compounds was also sensitive to mutations at N,
N+1,W-8 and numerous other sites in the outer pore (Jin et al., 2007).
Methoctramine inhibition had limited voltage-dependence and
was minimally affected by the introduction of GluN3 subunits or mu-
tation of G729 and R730, i.e. unlike PhTX-343 it remained potent
across the voltage and subunit range tested. Presumably its binding
site is not as deep as the other compounds meaning it would not be
inﬂuenced to the same degree by changes at the N and N+1 site,
and this was most obvious at highly negative Vh.Perhaps the most signiﬁcant ﬁnding from this study was that
GluN3B generally provided more resistance than GluN3A to block
by Mg2+, memantine and MK-801, and perhaps PhTX-343 at less
negative Vh. This cannot be explained by the substitutions at the N
and N+1 sites investigated in this study because both GluN3A and
GluN3B have G and R at the N and N+1 sites. There are several differ-
ences between the GluN3A and GluN3B sequences in the M2-M3 re-
gion that deﬁne the narrow part and vestibule of the pore. For
example, W/P (GluN3A/B) at +11, C/V at +27, E/D at +42 and I/T
at +44 within the M3 alpha helix (Fig. 1A) may affect binding direct-
ly, or indirectly through altered gating properties, leading to differ-
ences between GluN3A and GluN3B (Cordes et al., 2002). Other
regions such as the agonist binding domain, the N-terminal domain
and all the linker regions may be involved as these have been shown
to impact onMg2+ andmemantine potency inGluN1/GluN2 containing
NMDA receptors (Wrighton et al., 2008; Yuan et al., 2009). An approach
using chimeric GluN3A/B subunits, similar to that used by Wrighton
et al. (2008), may be useful in identifying these inﬂuential regions.
31D.W. McClymont et al. / European Journal of Pharmacology 686 (2012) 22–31In summary, the current study has conﬁrmed that the GluN3 sub-
units can reduce the potency of well categorised open-channel blockers
and has further shown that GluN3B is generally more effective than
GluN3A. The changes can be largely explained by the presence of G
and R at the N and N+1 sites for GluN3A but other residues in
GluN3B need to be explored to explain its higher resistance to channel
block.
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